ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ZIOP
- CUSIP: 98973P10
- Web: www.ziopharm.com
Capitalization:- Market Cap: $767.21 million
- Outstanding Shares: 130,701,000
Average Prices:- 50 Day Moving Avg: $5.92
- 200 Day Moving Avg: $6.34
- 52 Week Range: $4.45 - $7.88
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $6.49 million
- Price / Sales: 118.21
- Book Value: ($0.73) per share
- Price / Book: -8.04
Profitability:- EBIDTA: ($166,930,000.00)
- Net Margins: -2,600.79%
- Return on Assets: -44.55%
Debt:- Current Ratio: 5.31%
- Quick Ratio: 5.31%
Misc:- Average Volume: 1.32 million shs.
- Beta: 1.68
- Short Ratio: 23.66
Frequently Asked Questions for ZIOPHARM Oncology (NASDAQ:ZIOP)
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) released its quarterly earnings results on Monday, May, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.03. The firm had revenue of $1.60 million for the quarter, compared to analysts' expectations of $1.71 million. The firm's quarterly revenue was down 18.8% on a year-over-year basis. View ZIOPHARM Oncology's Earnings History.
Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?
4 equities research analysts have issued 1-year price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $9.50 to $23.00. On average, they expect ZIOPHARM Oncology's share price to reach $16.25 in the next year. View Analyst Ratings for ZIOPHARM Oncology.
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in June. As of June 30th, there was short interest totalling 36,003,899 shares, an increase of 0.5% from the June 15th total of 35,809,383 shares. Based on an average daily trading volume, of 1,370,404 shares, the days-to-cover ratio is presently 26.3 days. Currently, 28.2% of the company's stock are sold short.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Xencor (XNCR), Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), Neuroderm Ltd (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), Reata Pharmaceuticals (RETA) and Aclaris Therapeutics (ACRS).
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer
- Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
- Caesar J. Belbel, Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
- Murray Brennan, Non-Executive Lead Independent Director
- Randal J. Kirk, Director
- James A. Cannon, Independent Director
- Wyche Fowler Jr., J.D, Independent Director
- Timothy McInerney, Independent Director
Who owns ZIOPHARM Oncology stock?
Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?
How do I buy ZIOPHARM Oncology stock?
Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOPHARM Oncology stock can currently be purchased for approximately $5.87.
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $16.25 (176.83% upside) |
Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/1/2017 | HC Wainwright | Initiated Coverage | Buy -> Buy | $9.50 | High |  |
| 2/28/2017 | Griffin Securities | Reiterated Rating | Buy | $23.00 | N/A | |
| 1/12/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 8/10/2016 | Wells Fargo & Company | Upgrade | Underperform -> Market Perform | | N/A | |
| 7/18/2016 | Mizuho | Reiterated Rating | Neutral | $7.00 -> $5.00 | N/A | |
| 6/2/2016 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)Earnings History by Quarter for ZIOPHARM Oncology (NASDAQ ZIOP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/1/2017 | Q1 2017 | ($0.12) | ($0.15) | $1.71 million | $1.60 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.11) | ($0.11) | $1.45 million | $1.60 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.11) | ($1.01) | $1.52 million | $1.70 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.08) | ($0.09) | $1.89 million | $1.97 million | View | N/A | |
| 2/24/2016 | Q4 | ($0.07) | ($0.07) | $1.82 million | $1.92 million | View | N/A | |
| 11/2/2015 | Q315 | ($0.13) | ($0.14) | $1.19 million | $1.90 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.22) | ($0.11) | $57.70 million | $0.27 million | View | N/A | |
| 5/7/2015 | | ($0.13) | ($0.10) | $0.20 million | $0.30 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.14) | ($0.09) | $420.00 million | $0.34 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.12) | ($0.06) | $0.20 million | $0.63 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.17) | ($0.06) | $7.50 million | $0.20 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.10) | ($0.10) | $0.20 million | $0.20 million | View | N/A | |
| 3/3/2014 | Q413 | ($0.15) | ($0.09) | $0.20 million | $0.20 million | View | N/A | |
| 10/22/2013 | Q313 | ($0.17) | ($0.20) | | $0.20 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.24) | ($0.22) | $0.20 million | $0.20 million | View | N/A | |
| 3/18/2013 | Q4 2012 | ($0.29) | ($0.48) | $0.17 million | $0.20 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.28) | ($0.28) | $0.20 million | $0.20 million | View | N/A | |
| 8/2/2012 | | ($0.23) | ($0.29) | | | View | N/A | |
| 5/3/2012 | | ($0.22) | ($0.25) | | | View | N/A | |
| 2/29/2012 | | ($0.23) | ($0.24) | | | View | N/A | |
| 11/3/2011 | | ($0.28) | ($0.01) | | | View | N/A | |
| 8/1/2011 | | ($0.23) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q2 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q3 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
(Data provided by Zacks Investment Research)
Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ZIOPHARM Oncology (NASDAQ:ZIOP)Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 38.05%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/4/2015 | Murray Brennan | Director | Sell | 40,000 | $9.70 | $388,000.00 | |
| 2/9/2015 | Randal J Kirk | Director | Buy | 1,440,000 | $8.75 | $12,600,000.00 | |
| 10/29/2013 | Randal J Kirk | Director | Buy | 2,857,143 | $3.50 | $10,000,000.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for ZIOPHARM Oncology (NASDAQ:ZIOP)
Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 24 at 11:06 AM |
 | ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
feeds.benzinga.com - July 24 at 7:38 AM |
| ZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 11:29 AM |
 | Pfizer's Mylotarg Recommended by FDA Advisory Committee
www.zacks.com - July 13 at 11:31 AM |
 | ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + ... - GlobeNewswire (press release)
globenewswire.com - June 30 at 2:34 AM |
| Analysts Anticipate ZIOPHARM Oncology Inc (ZIOP) Will Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - June 29 at 9:16 AM |
 | Ziopharm Oncology (ZIOP) Reports Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
www.streetinsider.com - June 29 at 8:15 AM |
| Zacks: Brokerages Anticipate ZIOPHARM Oncology Inc (ZIOP) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - June 27 at 10:22 PM |
 | Bullish On Ziopharm
seekingalpha.com - June 22 at 2:54 PM |
| Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge
feeds.benzinga.com - June 20 at 3:55 PM |
| ZIOPHARM Oncology Inc (ZIOP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 10:00 AM |
 | ETFs with exposure to ZIOPHARM Oncology, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 4:18 PM |
| ZIOPHARM Oncology (ZIOP) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 3:15 PM |
| Ziopharm Oncology (ZIOP) Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at ASCO
www.streetinsider.com - June 6 at 3:16 AM |
| $1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - June 3 at 7:53 AM |
| ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:17 AM |
| Analysts Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - June 1 at 6:28 PM |
| ZIOPHARM Oncology Inc. (ZIOP) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - June 1 at 11:46 AM |
| ZIOPHARM Oncology Inc. (ZIOP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 26 at 10:14 AM |
| ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 26, 2017
finance.yahoo.com - May 26 at 9:15 AM |
 | BRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology
www.reuters.com - May 22 at 7:48 PM |
| ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 8:21 AM |
| Ziopharm Oncology (ZIOP) Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at ASCO
www.streetinsider.com - May 17 at 11:38 PM |
| ETFs with exposure to ZIOPHARM Oncology, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 7:54 PM |
 | ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock - Nasdaq
www.nasdaq.com - May 12 at 3:15 PM |
| ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock
finance.yahoo.com - May 12 at 3:15 PM |
| Ziopharm Oncology's stock tumbles after stock offering prices at deep discount
finance.yahoo.com - May 12 at 3:15 PM |
| Ziopharm Prices Secondary Offering
finance.yahoo.com - May 12 at 3:15 PM |
| ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 9, 2017
finance.yahoo.com - May 9 at 8:49 PM |
| Zacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS
www.americanbankingnews.com - May 8 at 2:24 PM |
| Griffin Securities Weighs in on ZIOPHARM Oncology Inc.'s Q2 2017 Earnings (ZIOP)
www.americanbankingnews.com - May 8 at 7:11 AM |
| ETFs with exposure to ZIOPHARM Oncology, Inc. : May 4, 2017
finance.yahoo.com - May 5 at 5:40 AM |
| ZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 7:07 PM |
| BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
www.reuters.com - May 3 at 9:32 AM |
| ZIOPHARM Oncology (ZIOP) Receives Daily Media Sentiment Score of 0.11
www.americanbankingnews.com - May 2 at 10:38 AM |
| Edited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM |
| ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM |
| Edited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT
finance.yahoo.com - May 2 at 8:03 AM |
| ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
finance.yahoo.com - May 2 at 8:03 AM |
| ZIOPHARM Oncology Inc. (ZIOP) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 1 at 11:40 PM |
| Investor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call
finance.yahoo.com - May 1 at 7:51 PM |
 | Ziopharm reports 1Q loss
marketbeat.com - May 1 at 4:33 PM |
| ZIOPHARM Oncology Inc. (ZIOP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 1 at 1:34 PM |
| ZIOPHARM Oncology (ZIOP) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM |
| ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - GlobeNewswire (press release)
globenewswire.com - April 26 at 5:27 PM |
| ZIOPHARM Oncology Inc. (ZIOP) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 26 at 4:36 PM |
| ZIOPHARM Oncology (ZIOP) Given News Sentiment Rating of 0.30
www.americanbankingnews.com - April 26 at 8:13 AM |
| ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - Yahoo Finance
finance.yahoo.com - April 24 at 8:16 AM |
| ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
feeds.benzinga.com - April 24 at 7:19 AM |
| ZIOPHARM Oncology (ZIOP) Given News Impact Score of -0.06
www.americanbankingnews.com - April 23 at 11:49 AM |
ZIOPHARM Oncology (ZIOP) Chart for Monday, July, 24, 2017
